# Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

> **NCT00854360** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 487 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis
- Hayfever

## Interventions

- **DRUG:** Beclomethasone dipropionate HFA Nasal Aerosol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00854360
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 487 (ACTUAL)
- **Last updated:** 2012-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854360, "Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00854360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*